Table 1.
Selected oncogenic drivers and their treatments in non-small cell lung cancer
|
|
Targeted therapy
|
ORR
|
PFS
|
OS
|
| EGFR | Erlotinib1[40] | 62%-83% | 9.7-13.1 mo | 19.3-26.3 mo |
| Gefitinib1[4] | 73.7% | 9.5 mo | 22 mo | |
| Afatinib1[5] | 56%-67% | 11.1 mo | 25.8 mo | |
| Dacomitinib1[127] | 74.9% | 14.7 mo | 34 mo | |
| Osimertinib1[128] | 80% | 18.9 mo | 38.6 mo | |
| ALK | Crizotinib1[53] | 75.5% | 11 mo | 57 mo |
| Ceritinib1[129] | 72.5% | 16.6 mo | NA | |
| Brigatinib0[130] | 79% | 24 mo | NA | |
| Alectinib1[131] | 82.9% | 35 mo | NA | |
| Lorlatinib1[54] | 76% | NA | NA | |
| ROS1 | Crizotinib1[132] | 63-72% | 15.9-19.2 mo | 51 mo |
| Lorlatinib1[133] | 62% | 19.3 mo | NA | |
| Entrectinib1[134] | 77% | 19 mo | NA | |
| BRAF | Dabrafenib-trametinib1[135] | 64% | 10.9 mo | 24.6 mo |
| MET | Crizotinib[50] | 32% | 7.3 mo | NA |
| Cabozantinib[136] | NA | NA | NA | |
| Capmatinib1[137] | 68% | 9.7 mo | NA | |
| Tepotinib[138] | 46% | NA | NA | |
| NTRK | Entrectinib1[139] | 70% | NA | NA |
| Larotrectinib1[140] | 75% | NA | NA | |
| RET | Selpercatinib1[141] | 85% | NA | NA |
| Pralsetinib1[121] | 70% | NA | NA | |
| KRAS | Sotorasib[142] | 32.2% | 10.2 mo | NA |
| Adagrasib[143] | 45% | NA | NA | |
| HER2 | Trastuzumab-deruxtecan[144] | 62% | 14 mo | NA |
| NRG1 | Afatinib[112] | NA | NA | NA |
1
Food and Drug Administration approved. ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; ROS1: c-ROS oncogene 1; NTRK: Neurotrophic receptor tyrosine kinase; RET: Rearranged during transfection; KRAS: Kirsten rat sarcoma; HER2: Human epidermal growth factor 2; NRG1: Neuregulin-1; BRAF: V-raf murine sarcoma viral oncogene homolog B. NA: Not available.